Skip to main content

Coronary Microvascular Dysfunction ID'd in 31.5 Percent With Psoriasis

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 20, 2023 -- Coronary microvascular dysfunction (CMD) occurs in 31.5 percent of patients with psoriasis, with disease severity and duration associated with increased risk, according to a study published in the October issue of the Journal of Investigative Dermatology.

Stefano Piaserico, M.D., Ph.D., from the University of Padova in Italy, and colleagues examined the prevalence and predictors of CMD in a cohort of 448 patients with psoriasis without clinical cardiovascular disease. The participants underwent assessment of coronary microcirculation by transthoracic Doppler echocardiography.

The researchers found that 31.5 percent of the patients had CMD. Independent associations with CMD were seen for higher Psoriasis Area and Severity Index (PASI), longer disease duration, presence of psoriatic arthritis, and hypertension. The risk for CMD was increased 5.8 and 4.6 percent in association with an increase of 1 point of PASI and one year of psoriasis duration, respectively.

"Our findings extend the observations of earlier small studies by showing a high prevalence of coronary microvascular dysfunction in asymptomatic patients with severe psoriasis and by showing that the excess microvascular dysfunction is independently associated with the severity and duration of psoriasis," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Tobacco Smoking Reduces the Odds of Psoriasis Improvement

WEDNESDAY, April 24, 2024 -- Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced...

AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis

FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are...

Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis

TUESDAY, March 5, 2024 -- For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.